More recently, the CD30 ligand (CD30L) was cloned and also characterized as a novel member of the TNF-like protein family." Like other members of this family, CD30 ligand exerts a plethora of biologic effects on its target cells." For instance, CD30L exerts mitogenic effects on activated T cells, promotes surface expression of the intercellular adhesion molecule-l (ICAM-l/CD54), and induces secretion of secondary cytokines such as interleukin-2 (IL-2), TNF-a, or interferon-y (IFN-y).7*L2*'3 Cultured "T-cell-like" HD cells have been shown to proliferatively respond to CD30L or to cross-linking with aCD30 antibodies, whereas "B-celllike" HD cells did not." CD30L enhances secretion of several cytokines such as IL-6, TNF, and LT-a by cultured H-RS cells.I4 CD30L also upregulates surface expression of CD54 and B7 family members on activated T cells and cultured H-RS ~e l l s .~. '~. '~ These molecules are frequently overexpressed in primary H-RS ~e 1 l s . l~"~ Increased CD30 surface expression as well as elevated serum levels of soluble CD30 (sCD30) have been associated with advanced disease and bulky tumor states and/or the presence of B-symptoms in HD patients.1'-2L High levels of sCD30 have also been linked to short disease-free survival and may thus be of prognostic significance." However, the role of CD30 in the pathogenesis of HD is still poorly understood. CD30 may provide proliferative responses either directly or may also spur proliferation of HD cells indirectly via induction of release of secondary cytokines such as IL-6, TNF, and LT-a. So far, the molecular mechanisms leading to cytokine secretion by HD cells remain enigmatic. The close association of CD30 surface expression, increased levels of sCD30 in sera of HD patients, and the presence of B-symptoms, likely to be caused by IL-6, TNF-a, and other polypeptides detectable in the serum of HD suggests that activation of CD30 may play a causative role for the release of secondary cytokines by HD cells.I4 To further substantiate this notion, we have examined the ability of various monoclonal antibodies (MoAbs) capable of binding and activating CD30LL.12 to induce release of IL-6 and have also investigated some of the underlying mechanism.
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Vienna, UT), 100 U/mL penicillin, 10 pg/mL streptomycin, and 2 mmol/L L-glutamine (referred to as standard culture medium [SCM] ). Cells (l@/mL) were exposed to immobilized MoAbs M44 or M67 (IO pg/mL), both known to specifically target and activate CD30.".'* HDLM-2 cells and KM-H2 cells were also cocultured on CV-IEBNA cells (104 cells/mL) that were transfected with either the empty vector (CV-I/HAV) or the full-length human CD30L cDNA (CV-UCD30L) using the diethyl aminoethyl (DEAE)-Dextran method as previously described." Cells were fixed with 1% paraformaldehyde for 5 minutes at 25T, as detailed elsewhere.".'2. '4 Assessment of cytokine levels in cell-free culture supernatants. Levels of IL-6 were determined in cell-free culture supernatants by commercially available enzyme-linked immunosorbent assays (ELISA; R&D Systems, Minneapolis, MN) according to the manufacturer's guidelines.
RNA extraction and Northern blot analysis. Northern blot analysis of IL-6 mRNA expression was performed as previously described in d e~~i l . '~.~' Briefly, cells were resuspended in guanidinium isothiocyanate (Sigma, Miinchen, Germany) and extracted with an equal volume of acetate/EDTA-equilibrated phenol (60°C for 25 minutes with frequent vortexing). The aqueous phase was recovered after centrifugation and extracted once with an equal volume of phenoV chloroform and twice with chloroform. The resulting RNA was precipitated overnight at -20°C with 2.5 v01 of ethanol. The total RNA from each sample was then electrophoresed on a 1% agarose gel containing 20 mmol/L sodium borate, pH 8.3, 0.5 mmol/L EDTA, and 3% formaldehyd. The RNA was transferred to nitrocellulose paper (Schleicher and Schuell, Dassel, Germany) in lox SSC (1.5 m o m sodium chloride and 150 mmol/L sodium citrate) using capillary blotting overnight. The blots were baked and prehybridized at 65°C in 7% sodium dodecyl sulfate (SDS), 1OX Denhardt's (50X Denhardt's = 1% Ficoll, 1% bovine serum albumin [BSA] , and 1% polyvinyl-pyrolidone), 5X SSC, and 50 pg/mL salmon sperm DNA (Sigma). IL-6 mRNA expression was detected using the 0.55-kb Taq UBan I fragment of the pGEM4-IL-6 plasmid, kindly provided by Dr T. Kishimoto (University of Osaka, Osaka, Japan). Control hybridizations used a cDNA probe encoding the house-keeping gene GAPDH. The cDNA fragments were radiolabeled by random priming with Q(~'P)-~CTP (>6,000 Cilmmol; Amersham Buchler, Braunschweig, Germany). The blots were then washed at 55°C in 1% SDS/l X SSC and were autoradiographed with a Kodak X-omat film (Eastman Kodak, Rochester, NY) at -70°C with an intensifying screen.
Nuclear run-on assays. For nuclear run-on transcription assays, HDLM-2 cells (10' ) were lysed in a lysis buffer consisting of 10 mmol/L Tris-HCL, 5 mmom KCL, 3 mmol/L MgC12, and 0.5% Nonidet P 40 (Sigma) and were washed in ice-cold phosphate-buffered saline (PBS). Nuclei were incubated at 26°C in 15% glycerol; 70 m m o K KCl; 2.5 mmolL MgCl'; 10 mmol/L EDTA; 4 mmoV L levels each of ATP, CTP, and GTP; 2 mmol/L U P ; 0.5 mmom dithiothreitol; 60 U/mL RNasin (Boehringer Mannheim, Mannheim, Germany) in the presence of 100 pCi of [32P]UTP (3,000 Ci/mmol; Amersham Buchler) for 30 minutes. The mixture was digested with DNase I and precipitated in 70% ethanol used for hybridization consisting of 5 X 10' c p d m L of hybridization buffer (50% formamide, 2X SSC, 1% SDS, 5X Denhardt's solution, 5 pg/mL tRNA). Filters contained 10 pg each of linearized plasmids containing the human IL-6 cDNA, the empty vector, or the GAPDH cDNA immobilized on nitrocellulose (Schleicher and Schuell) after blotting with a slot-blot apparatus (Schleicher and Schuell). After hybridization at 42°C for 3 days, filters were rinsed in 2X SSC at 55"C, 2 x SSC containing 10 pg/mL RNAse at 37°C and finally 0 . 5~ SSC at 55°C. for 30 minutes each time, and were exposed to Kodak X-omat films for 10 days.
Preparation of nuclear proteins and electrophoretic mobility shij assays (EMU). EMSA were performed essentially as previously de~cribed.2~ Briefly, nuclear extracts were prepad from HDL"2 cells which had (or had not) been cross-linked to M44 according to the The end-labeled oligodesoxynucleotides or isolated DNA fragments (1 ng; approximately, 10, OOO cpm) were incubated with 10 pg nuclear proteins in an incubation buffer, as previously described,27 for 20 minutes at room temperature. For competition assays, incubation was performed in the presence of 25-fold molar excess of unlabeled double-stranded oligomers containing the NF-KB recognition sequence or a mutated binding sequence. The reaction products were analyzed by electrophoresis in a 5% polyacrylamide gel followed by autoradiography. In selected experiments, antibodies to ~~~-N F -K B , ~~O -N F -K B , c-Rel, and Rel-B (Santa Cruz Inc, Santa Cruz, CA) were used to further identify the nature of the proteins bound to the NF-KB recognition sequence. These supershift assays were performed with an incubation buffer containing 20 mmolL HEPES, pH 7.9, 20% (vol/vol) glycerol, 300 mmol/L KCl, 0.5 mmol/L EDTA, 10 mmol/L dithiotreitol (DTT), 100 mmol/L phenylmethylsulfonyl fluoride (PMSF), 40% (v011 vol) Ficoll, 1 pg BSA (10 mg/mL), and 0.1 pg polydeoxyinosinicdeoxycytidylic acid (poly-dIdC; 1 mg1mL).
Transient transfection assays. Promoter constructs used for transient transfection assays have been described before.27 In addition, the 66-bp fragment containing the NF-KB binding site of the IL-6 promoter was cloned into the same vector (pTKGH) containing the heterologous thymidine kinase promoter linked to the human growth hormone as reporter gene. Transient transfections were performed using commercially available liposomes (Boehringer Mannheim) as detailed by the manufacturer. Cells were cultured in the presence of liposome-complexed DNA for 24 hours, split, and cultured on plates coated with the M44 MoAb or an irrelevant isotype identical monoclonal antibody for additional 24 hours followed by analysis of human growth hormone activity (hGH) in cell-free culture supernatants using an hGH-specific EL4 (Eurogenetics, Tessenderio, Belgium).
5'TCGAGAGAAAATGTGGGGA"ITCCAGAGGC"; NF-

RESULTS
In the first
set of experiments we have investigated whether activation of CD30 is associated with secretion of IL-6. To this end, HDLM-2 and KM-H2 cells were either exposed to CD3OL or cross-linked to either an agonistic anti-CD30 MoAb M44 or an irrelevant isotype-matched antibody for up to 96 hours. As shown in Fig 1, both M44 as well as CD30L were capable of inducing secretion of IL-6 by HDLM-2 cells and KM-H2 cells in a time-dependent fashion, whereas cross-linking to the isotype-identical control MoAb failed to promote L -6 synthesis during the timeperiod investigated (Fig 1) . U-937 leukemia cells that do not express CD30, failed to respond to M44 or CD30L with release of IL-6 (data not shown).
Secretion of L -6 by HDLM-2 cells after stimulation with M44 was preceded by enhanced synthesis of IL-6 transcripts.
For HDLM-2 constitutively accumulate L -6 mRNA that is further enhanced by threefold 12 to 24 hours after cross-linking of HDLM-2 cells to M44 and decreased to starting levels within the following 24 hours (Fig 2) . Cross-linking to an isotype-identical irrelevant MoAb failed to enhance L -6 mRNA accumulation in these cells over the 48-hour observation period (data not shown). Enhanced L -6 mRNA accumulation was also observed in HDLM-2 cells cultured in the presence of CV-IEBNA cells transfected with the fulllength human CD30-ligand cDNA, but not in cells transfected with the vector only (Fig 2) . Similarly, KM-H2 cells also responded to either &D30 cross-linking or CD30L stimulation with enhanced accumulation of IL-6 mRNA transcripts (data not shown).
Transcriptional run-off assays furthermore indicated that L -6 mRNA accumulation after cross-linking of HDLM-2 cells to M44 was, at least in part, due to transcriptional 2445 activation of the L 6 gene (Fig 3) . Cross-linking HDLM-2 cells to M44 for 30 minutes was sufficient to enhance the transcriptional rate of the IL-6 gene by twofold to threefold, whereas the transcriptional activity of the GAPDH-gene remained unaffected (Fig 3) .
To further delineate the molecular mechanism responsible for transcriptional activation of the IL-6 gene induced by cross-linking to CD30, a series of deleted IL-6 promoter constructs was in~trumental.~' These constructs were transiently transfected into HDLM-2 cells followed (or not) by cross-linking to M44 and quantitation of human growth hormone activity as a reporter gene product in cell-free supernatants. The results summarized in Fig 4 indicate that crosslinking of CD30 to M44 resulted in transcriptional activation of the L-6 promoter in HDLM-2 cells by fourfold to fivefold. Deletion of the IL-6 promoter up to position -107 did not significantly interfere with the capacity of CD30 activation to promote transcriptional activity. This deleted construct still harbors the recognition site for the NF-KB transcription factor that has previously been showed in several studies to be essential for L -6 gene activati~n.~"~' Deletion of the AP-l binding site (position -283 to -277) or deletion of the NF-IL6 binding site (position -158 to -145) did not prevent transcriptional activation of the L-6 promoter in HDLM-2 cells on cross-linking to M44 antibody (Fig 4) . Deletion of the L-6 promoter up to position -49, which eliminates the NF-KB binding site as well as deletion of the NF-KB transcription factor binding site in the context of the intact L -6 promoter resulted in complete loss of transcriptional activation of the promoter by CD30 in HD cells (Fig 4) . To exclude that the deleted 66-bp fragment contained binding sites for additional transcription factors that may also contribute to the transcriptional activation of the IL-6 promoter by CD30 activation, gel mobility shift experiments were performed using this fragment as a probe. DNA-protein complexes formed by nuclear extracts obtained from cells which had or had not been cross-linked to CD30 did not differ from those obtained when probed with the oligonucleotide that contains the NF-KB binding site only. Moreover, DNA-protein complex formation was relieved by excess unlabeled NF-KB oligonucleotide, suggesting that the 66-bp DNA fragment deleted is targeted by NF-KB only (data not shown).
The capacity of CD30 to promote functional activation of the NF-KB transcription factor was also shown by demonstrating that a heterologous promoter construct carrying the NF-KB recognition site responded to cross-linking of M44 with enhanced activation in HDLM-2 cells, whereas a control construct, not containing the NF-KB recognition sequence, failed to do so (Fig 5) . Similarly, the deleted 66-bp fragment of the IL-6 promoter containing the NF-KB recognition site (position -1 15 to -49) confered a sixfold to eightfold enhanced activation in HDLM-2 cells after CD30 cross-linking of the heterologous thymidine kinase promoter Moreover, gel mobility shift assays showed that crosslinking of M44 to HDLM-2 cells was sufficient to promote binding activity of NF-KB, whereas cross-linking of an isotype-identical MoAb had no effect on NF-KB binding activ- (Fig 5) . specific agonistic MoAb results in nuclear translocation of the NF-KB transcription factor. This leads to transcriptional activation of the IL-6 gene, resulting in enhanced accumulation of IL-6 mRNA known from previous studies to be constitutively transcribed by H-RS cells22.'2." and finally in enhanced release of the IL-6 protein. This response appeared to be specific in that it could be duplicated by another agonistic antibody (M67)" or by CD30L, whereas an isotype-matched irrelevant antibody failed to promote IL-6 release by these cells. Truncation of the IL-6 promoter up to the NF-KB site immediate 5' of the transcription start site did not interfere with transcriptional activation by M44 cross-linking, suggesting that several transcription factor binding sites such as AP-I, NF-IL-6, or CK-I did not significantly contribute to the transcriptional regulation of the IL-6 gene by CD30 activation. In addition, deletion of a 66-bp fragment containing the NF-KB binding site within the intact IL-6 promoter prevented transcriptional activation of the IL-6 promoter upon CD30 activation. As shown in gelmobility shift assays, this 66-bp fragment did not harbor any other binding sites apart from that recognized by members of the NF-KB protein family.
Moreover, insertion of the NF-KB recognition site or the 66-bp fragment containing the NF-KB DNA-binding site of the IL-6 promoter 5' of a heterologous thymidine kinase promoter was also sufficient to confer transcriptional activation through CD30. Activation of CD30 enhanced NF-KB binding activity time-dependently. Supershifts performed in the presence of MoAbs recognizing distinct members of the NF-KBk-rel transcription factor family furthermore showed that the NF-KB complex induced by the CD30 signaling pathway consists of p65/Rel-A, p50, and c-Re1 subunits; the rel-B protein was not detectable upon CD30 activation in HDLM-2 cells.
Previous studies have shown that primary and cultured H-RS cells constitutively transcribe the IL-6 gene. A doublestranded oligodesoxynucleotide harboring the NF-KB recognition sequence of the IL-6 promoter was inserted (pNF-kappaB/TKGH) or not (pTKGH) 5' of a heterologous herpes thymidine kinase (TKI promoter linked to the hGH gene as a reporter gene. In addition, the 66-bp fragment of the IL-6 promoter containing the NF-KB binding site was fused to the TK promoterlhGH reporter gene construct (p66bp-NFkappaB/TKGH). HDLM-2 cells were transiently transfected with either construct, split 24 hours after transfection, and cross-linked t o M44 or control MoAb for an additional 24 hours. Thereafter, hGH activity was quantitated in cell-free culture supernatants using a commercially available hGH EIA. Results are expressed as mean ? SD of three independent experiments. tional regulation of the IL-6 gene, our data also indicate that the NF-KB recognition sequence is of crucial importance for the regulation of this gene.z7-3' Although several other transacting molecules have been identified in the promoter of the IL-6 gene, including an AP-I or an NF-IL6 site,"" .. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From these molecules do not appear to play a major functional role for IL-6 gene regulation in response to CD30 in cultured HD cells. The pivotal role of the NF-KB transcription factor for regulation of the IL-6 gene has previously been shown in "knock out" mice.".31
The signaling events leading to nuclear translocation and activation of NF-KB by CD30 are still unknown. Within the intracellular signal-transmitting domain of CD30, no significant homology to other members of the TNF/NGF receptor superfamily or other cytokine receptor families exists." Nevertheless, several members of the TNF-receptor superfamily share common biologic activities, including activation of the NF-KB transcription factor.'6 The type I TNFreceptor has been shown to mediate NF-KB activation through a stretch of 40 AA in the distal cytoplasmatic tail." This region is also involved in activation of acidic sphingomyelinase and in TNF-a-mediated cytot~xicity.'~.~~ The type I1 TNF-receptor has more recently been shown to induce NF-KB activation through recruitment of two novel TNFreceptor-associated factors (TRAF) 1 and 2.'' These molecules appear to constitute a growing family of signal transducing proteins involved in signaling of the TNF-receptor family. A homologous protein, designated CRAFI/CD40BP/ LAP-l (TRAF 3), has recently been identified to be associated with the CD40 r e c e p t~r .~.~~ It is tempting to speculate that similar molecules are involved in transmitting signals from the CD30 receptor and are also involved in activation of the NF-KB transcription factor.
Besides regulating IL-6 gene expression, the NF-KB transcription factor also significantly contributes to the transcriptional regulation of several other cytokine genes such as TNF, IFN-y, or IL-2; cytokine receptor genes; and adhesion It is therefore tempting to speculate that the activation of NF-KB in response to CD30L leads to the release of other cytokines, surface expression of cytokine receptors and adhesion molecules, and may thus represent an important factor in the promotion of cellular activation and development of B-symptoms associated with HD.
